With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.7467-91-6,Quinoxalin-6-ol,as a common compound, the synthetic route is as follows.,7467-91-6
TMAD (0.55 g, 3.20 mmol) was added to a stirred mixture of 2-[3-(4-tert-butoxycarbonyl-1-piperazinyl)-pyrazinyloxy]ethanol (1.00 g, 3.08 mmol), 6-hydroxyquinoxaline* (0.45 g, 3.08 mmol) and triphenylphosphine (0.85 g, 3.24 mmol) in THF (10 mL) at room temperature. After 20 h, the reaction mixture was concentrated and put through a silica column using toluene/EtOAc (1 : 1) as eluent. The chromatographic procedure was repeated once. Solvents were removed in vacuo and the resulting N-t-BOC derivative was treated with dichloromethane/TFA/H2O (50: 45: 5; 20 mL) for 30 min with stirring. The reaction mixture was concentrated, dissolved in 0.1 M aqueous HCl and washed with toluene. The aqueous phase was frozen and lyophilized, dissolved in EtOH and concentrated to give 0.843 g (70percent) of the title compound. HRMS m/z calcd for C18H20N6O2 (M) + 352.1648, found 352.1642. *Prepared as described in J. Org. Chem. 1951,16, 438-442.
As the paragraph descriping shows that 7467-91-6 is playing an increasingly important role.
Reference£º
Patent; BIOVITRUM AB; WO2004/9586; (2004); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider